PRINCIPLE, the UK’s national priority clinical trial of COVID-19 treatments for recovery at home, has launched a new trial arm assessing favipiravir. Favipiravir is an antiviral drug licenced in Japan to treat influenza. People aged 50 - 64 with certain underlying health conditions or shortness of breath from COVID-19, or aged over 65, are eligible to join the favipiravir arm within the first 14 days of experiencing COVID-19 symptoms or receiving a positive test. People can join from anywhere in the UK, either online, over the phone or via a healthcare professional. If you think a patient may be interested in joining the study, visit the website.